InMed Pharmaceuticals Inc. (INM) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1445-885 WEST GEORGIA ST. VANCOUVER, BC V6C 3E8 |
| State of Incorp. | BC |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 MRQ | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 3,500 | 6,600 | 8,957 | 6,222 | 7,410 | |||
| Cash and cash equivalent | 3,419 | 6,572 | 8,913 | 6,177 | 7,363 | |||
| Short-term investments | 41 | 43 | 44 | 45 | 46 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 40 | (15) | ||||||
| Receivables | 263 | 353 | 260 | 88 | 12 | |||
| Inventory, net of allowances, customer advances and progress billings, including: | 1,103 | 1,244 | 94 | 2,491 | ||||
| Inventory | 1,103 | 1,244 | 1,616 | 2,491 | ||||
| Other undisclosed inventory, net of allowances, customer advances and progress billings | (1,523) | |||||||
| Deferred costs | 112 | |||||||
| Other undisclosed current assets | 604 | 492 | 2,021 | 797 | 845 | |||
| Total current assets: | 5,470 | 8,690 | 11,332 | 9,598 | 8,378 | |||
| Noncurrent Assets | ||||||||
| Property, plant and equipment | 1,231 | 1,250 | 723 | 327 | ||||
| Intangible assets, net (including goodwill) | 1,701 | 1,783 | 1,946 | 2,109 | 1,062 | |||
| Intangible assets, net (excluding goodwill) | 1,701 | 1,783 | 1,946 | 2,109 | 1,062 | |||
| Other noncurrent assets | 100 | 100 | 105 | 177 | 15 | |||
| Other undisclosed noncurrent assets | 904 | |||||||
| Total noncurrent assets: | 3,032 | 3,133 | 2,775 | 3,190 | 1,403 | |||
| TOTAL ASSETS: | 8,502 | 11,823 | 14,106 | 12,788 | 9,781 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 1,371 | 1,654 | 1,609 | 2,415 | 2,135 | |||
| Accounts payable | 575 | 41 | 544 | |||||
| Accrued liabilities | 337 | 256 | 542 | |||||
| Other undisclosed accounts payable and accrued liabilities | 459 | 1,357 | 522 | 2,415 | 2,135 | |||
| Deferred rent credit | 16 | |||||||
| Other undisclosed current liabilities | 420 | 318 | 376 | 904 | 80 | |||
| Total current liabilities: | 1,791 | 1,972 | 2,001 | 3,320 | 2,215 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation: | 389 | 189 | ||||||
| Liabilities, other than long-term debt | 529 | 645 | 16 | |||||
| Operating lease, liability | 529 | 645 | 16 | 389 | 189 | |||
| Other undisclosed noncurrent liabilities | (389) | (189) | ||||||
| Total noncurrent liabilities: | 529 | 645 | 16 | 389 | 189 | |||
| Total liabilities: | 2,320 | 2,617 | 2,017 | 3,709 | 2,405 | |||
| Equity | ||||||||
| Equity, attributable to parent | 6,182 | 9,206 | 12,090 | 9,079 | 7,377 | |||
| Common stock | 84,537 | 82,784 | 77,620 | 70,718 | 60,587 | |||
| Additional paid in capital | 34,845 | 35,369 | 35,741 | 31,684 | 21,513 | |||
| Accumulated other comprehensive income | 129 | 129 | 129 | 129 | 129 | |||
| Accumulated deficit | (113,329) | (109,076) | (101,400) | (93,453) | (74,852) | |||
| Total equity: | 6,182 | 9,206 | 12,090 | 9,079 | 7,377 | |||
| TOTAL LIABILITIES AND EQUITY: | 8,502 | 11,823 | 14,106 | 12,788 | 9,781 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 4,832 | 4,598 | 4,136 | 1,089 | |||
| Cost of revenue | (3,386) | (3,497) | (2,424) | (546) | |||
| Cost of product and service sold | (465) | (1,806) | (309) | (546) | |||
| Other undisclosed gross profit | 263 | (309) | |||||
| Gross profit: | 1,710 | 1,101 | 1,403 | 544 | |||
| Operating expenses | (9,577) | (9,297) | (9,782) | (17,808) | (9,938) | ||
| Other undisclosed operating loss | (1,336) | ||||||
| Operating loss: | (7,868) | (8,196) | (8,379) | (18,600) | (9,938) | ||
| Nonoperating income (expense) | 313 | 528 | (48) | (21) | (265) | ||
| Investment income, nonoperating | 209 | 528 | 96 | 259 | |||
| Loss, foreign currency transaction, before tax | (62) | (48) | (118) | (163) | |||
| Other nonoperating expense | (360) | ||||||
| Interest and debt expense | (352) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (7,906) | (7,668) | (8,427) | (18,622) | (10,203) | ||
| Other undisclosed income from continuing operations before income taxes | 492 | ||||||
| Loss from continuing operations before income taxes: | (7,906) | (7,668) | (7,935) | (18,622) | (10,203) | ||
| Income tax expense | (7) | (13) | |||||
| Other undisclosed loss from continuing operations | (7) | ||||||
| Loss from continuing operations: | (7,913) | (7,676) | (7,948) | (18,622) | (10,203) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (18,622) | (10,203) | |
| Other undisclosed net income | 15,848 | 37,222 | 20,403 | ||||
| Net income (loss): | (7,913) | (7,676) | 7,900 | 18,600 | 10,200 | ||
| Other undisclosed net loss attributable to parent | (15,848) | (37,200) | (20,403) | ||||
| Net loss available to common stockholders, diluted: | (7,913) | (7,676) | (7,948) | (18,600) | (10,203) | ||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (7,913) | (7,676) | 7,900 | 18,600 | 10,200 | ||
| Comprehensive income (loss): | (7,913) | (7,676) | 7,900 | 18,600 | 10,200 | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (37,200) | (19,973) | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (7,913) | (7,676) | 7,900 | (18,600) | (9,773) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.